Content in this topic
SARS-CoV-2 uses a number of key proteins to infect us, including its main protease. New research has found hepatitis C drugs can bind this protein.
Several developers have reported incredible coronavirus vaccine progress, so when will we have a COVID-19 vaccine ready for distribution?
The University of Oxford's COVID-19 vaccine was up to 90% effective in a phase 3 trial and could be easier to distribute than other coronavirus vaccines.
Coronavirus immunity might last for years, according to a new study that measured the levels of virus-fighting immune cells in COVID-19 survivors.
The FDA has authorized an at-home COVID-19 test that delivers results in 30 minutes, but you can’t get it without a prescription.
Another win for mRNA vaccines: Moderna’s coronavirus vaccine appears to be 94.5% effective at preventing COVID-19, according to initial trial data.
The Pfizer COVID-19 vaccine appears to be 95% effective at preventing coronavirus infections, according to an early analysis of a Phase 3 trail.
COVID-19 blood clots may be caused by autoantibodies, which attack the body’s own tissues and organs instead of intruders.
There may be an increase in cases of COVID-19 this winter as people move indoors, but there are actions we can take to prevent it.